T Regulatory cells

Developed for: acute respiratory distress syndrome · amyotrophic lateral sclerosis · COVID-19
Investigated by: Masonic Cancer Center, University of Minnesota · Massachusetts General Hospital · National Cancer Institute (NCI) · National Institutes of Health (NIH) · North East Amyotrophic Lateral Sclerosis Consortium · Stanford University
+2 more
· The Center for Clinical and Translational Sciences (CCTS) Clinical Research Unit at The University of Texas Health Science Center at Houston · The Methodist Hospital Research Institute

20172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 11 trial
Phase 1	NCT04737161	Mar 2021 → Sep 2022	COVID-19, acute respiratory distress syndrome	Stanford University	Withdrawn	No outcome recorded Stop: Business
Phase 22 trials
Phase 2	NCT04055623	Aug 2019 → May 2022 overdue	amyotrophic lateral sclerosis	The Methodist Hospital Research Institute	Active not recruiting	No outcome recorded
Phase 2	NCT02118311	Jun 2016 → Sep 2018	hematopoietic and lymphoid cell neoplasm	Masonic Cancer Center, University of Minnesota	Withdrawn	No outcome recorded

Every value below carries the sentence it was read from. 4 sources stand behind the page.

Field	Value	Cited text
Known as	T regulatory cells	“T-regulatory cells taken from a patient, increased in number in a lab, and returned through monthly intravenous (IV) infusions back to same patient + 3 times per week...” NCT04055623 ↗ 2 NCT04737161 ↗ NCT02118311 ↗
Modality	Cell therapy	“The nTreg cells (manufactured from a 3rd cord blood unit) are infused” NCT02118311 ↗
Route	Intravenous	“Treg infusions (1 × 106 cells/kg) IV every 4 weeks” PMID 36038262 ↗ Aug 2022